Unlocking the Potential: Lavras Gold Files Amended Technical Reports

Lavras Gold Corp. Updates Technical Reports for Butiá and Cerrito Projects Overview Toronto, Ontario–(Newsfile Corp. – November 26, 2024) – Lavras Gold Corp. (TSXV: LGC) (OTCQX: LGCFF) (“Lavras Gold” or the “Company”) has announced updates to its Butiá and Cerrito technical reports following a review by the Ontario Securities Commission (OSC). Details of the Update…

Read More

“Unleashing the Power of Music: A Must-Watch Video for Music Lovers!”

Mizuho Bank’s Vishnu Varathan on China’s Economic Rebalancing and Trump Tariffs Struggles in Rebalancing China has been facing challenges in rebalancing its economy, especially in the midst of escalating tariffs imposed by President Trump. Vishnu Varathan from Mizuho Bank has highlighted the difficulties China is facing as they try to shift their economy towards a…

Read More

“MYND Life Sciences Announces Exciting Shares-for-Debt Transaction: A Win-Win Solution for Company and Investors!”

MYND Life Sciences Inc. Enters Shares for Debt Agreements to Settle Outstanding Indebtedness Vancouver, British Columbia–(Newsfile Corp. – February 11, 2025) Introduction MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) (“MYND” or the “Company”) is a clinical-stage life sciences company dedicated to developing and commercializing drug therapies and diagnostics to enhance the monitoring and…

Read More

Skyworks Solutions, Inc.: Schall Law Firm Invites Swks Investors to Join Securities Class Action Lawsuit – Here’s How!

Breaking News: Skyworks Solutions Class Action Lawsuit – What Does It Mean for Investors and the World? In a recent development, The Schall Law Firm has announced a class action lawsuit against Skyworks Solutions, Inc. (NASDAQ: SWKS) for alleged securities law violations. The lawsuit, filed on March 7, 2025, accuses the Company of violating §§10(b)…

Read More

Innovative and Articulate: Protagenic Therapeutics Announces Pricing of Private Placement for $12.75 Million

Protagenic Therapeutics Announces Purchase Agreement for 1,948,295 Shares of Common Stock New York, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) Biopharmaceutical Innovation Protagenic Therapeutics, a leader in biopharmaceutical innovation, has recently made a significant announcement regarding a purchase agreement for the sale of an aggregate of 1,948,295 shares of common…

Read More